stockportfolio.pro
Stocks / ATRC vs VIR
ATRC vs VIR
AtriCure, Inc. and Vir Biotechnology, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| AtriCure, Inc. (ATRC) | Vir Biotechnology, Inc. (VIR) | |
|---|---|---|
| Market cap | $1.4B | $1.4B |
| Revenue (latest FY) | $534.53M | $68.56M |
| Net income (latest FY) | $-11.45M | $-437.99M |
| Revenue growth (5y CAGR) | 20.9% | -2.1% |
| Net margin | -2.1% | -638.9% |
| Return on equity | -2.3% | -57.2% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 2 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ATRC — free Open VIR — freeFrequently asked questions
Which is bigger, ATRC or VIR?
AtriCure, Inc. is larger by market capitalization — $1.4B versus $1.4B.
Which grows faster, ATRC or VIR?
Over the last five fiscal years, AtriCure, Inc. grew revenue faster — 20.9%/yr versus -2.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.